Phase II study of sunitinib as first-line treatment of...

Annals of Oncology 2011 / 12 Vol. 22; Iss. 12

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

Bellmunt, J., Gonzalez-Larriba, J. L., Prior, C., Maroto, P., Carles, J., Castellano, D., Mellado, B., Gallardo, E., Perez-Gracia, J. L., Aguilar, G., Villanueva, X., Albanell, J., Calvo, A.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdr023
Date:
December, 2011
File:
PDF, 231 KB
english, 2011
Conversion to is in progress
Conversion to is failed